Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension

R C HeelG S Avery


Atenolol is a beta-selective (cardioselective) adrenoceptor blocking drug without partial agonist or membrane stabilising activity. Its profile of action most closely resembles that of metoprolol which differs only in that it has some membrane stabilising activity. Atenolol has been well studied and is effective in the treatment of hypertension and in the prophylactic management of angina. Its narrow dose response range obviates the need for highly individualised dose titration. In patients with angina its long duration of beta-blocking activity allows once daily dosage, whereas other beta-blockers, unless in sustained release dosage forms, need to be given in divided doses. Other beta-blockers can be given once daily in hypertension, but at presnt the evidence for effective control with a once daily regimen is more convincing with atenolol. Further studies are need to clarify any important differences in blood pressure control between the various beta-blocking drugs, both in conventional or sustained release dosage forms. As with metoprolol, atenolol is preferable to non-selective beta-blockers in patients with asthma or diabetes mellitus. Atenolol has been well tolerated in most patients, its profile of adverse reactions gene...Continue Reading


Jul 1, 1985·Journal of Clinical Pharmacology·V M CampeseS G Massry
Jan 1, 1982·Journal of Psychoactive Drugs·J Buffum
Jan 1, 1982·The Journal of International Medical Research·J J Houtzagers, D R Chadha
Jan 7, 1999·Drug Development and Industrial Pharmacy·R IglesiasA Concheiro
Nov 6, 2018·Rapid Communications in Mass Spectrometry : RCM·Amanda V QuaresmaRobson J C F Afonso
Jun 1, 1988·Archives of Sexual Behavior·R C RosenA W Jekelis
Jun 17, 1982·The New England Journal of Medicine·W H Frishman
Oct 1, 1986·Naunyn-Schmiedeberg's Archives of Pharmacology·K SonoM Fujiwara
Sep 1, 1989·The Journal of International Medical Research·H Vergin, V Nitsche
Apr 1, 1992·Journal of Clinical Pharmacology·R L WilliamsL B Hogan
Jan 16, 2008·European Journal of Clinical Pharmacology·John M KovarikRobert L Schmouder
Oct 12, 2011·Journal of Veterinary Pharmacology and Therapeutics·K H KhorP C Mills
Nov 1, 1982·Acta Neurologica Scandinavica·T A LarsenD B Calne
Jan 1, 1985·Acta Medica Scandinavica. Supplementum·U Thadani
Oct 2, 2004·American Journal of Physiology. Heart and Circulatory Physiology·M-H HuangG A Ewy
Aug 27, 1981·The New England Journal of Medicine·J Koch-Weser, W H Frishman
Jul 16, 2008·Current Hypertension Reports·Domenic A Sica, Henry R Black
Aug 1, 1991·The Journal of Pharmacy and Pharmacology·P AgonJ M Kaufman
Dec 17, 2004·Journal of Clinical Pharmacology·Mary F HebertThomas R Easterling
Oct 25, 2020·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Adam HermawanRohmad Yudi Utomo

Related Concepts

Adrenergic beta-Antagonists
Angina Pectoris
Central Nervous System
Hypertensive Disease

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.